CureVac Future Growth
Future criteria checks 2/6
CureVac is forecast to grow earnings and revenue by 52.6% and 31.6% per annum respectively. EPS is expected to grow by 50.8% per annum. Return on equity is forecast to be -85.3% in 3 years.
Key information
52.6%
Earnings growth rate
50.8%
EPS growth rate
Biotechs earnings growth | 31.4% |
Revenue growth rate | 31.6% |
Future return on equity | -85.3% |
Analyst coverage | Good |
Last updated | 08 May 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 122 | -67 | -64 | -21 | 6 |
12/31/2025 | 79 | -126 | -147 | -105 | 7 |
12/31/2024 | 59 | -184 | -227 | -227 | 8 |
12/31/2023 | 54 | -260 | -323 | -268 | N/A |
9/30/2023 | 43 | -302 | -335 | -273 | N/A |
6/30/2023 | 38 | -301 | -325 | -249 | N/A |
3/31/2023 | 50 | -291 | -338 | -249 | N/A |
12/31/2022 | 67 | -249 | -379 | -286 | N/A |
9/30/2022 | 97 | -122 | -527 | -420 | N/A |
6/30/2022 | 115 | -219 | -758 | -659 | N/A |
3/31/2022 | 117 | -313 | -782 | -673 | N/A |
12/31/2021 | 103 | -412 | -861 | -733 | N/A |
9/30/2021 | 68 | -468 | -228 | -109 | N/A |
6/30/2021 | 44 | -361 | N/A | N/A | N/A |
3/31/2021 | 56 | -219 | 250 | 329 | N/A |
12/31/2020 | 49 | -129 | 475 | 522 | N/A |
9/30/2020 | 50 | -107 | 36 | 62 | N/A |
3/31/2020 | 17 | -102 | -82 | -67 | N/A |
12/31/2019 | 17 | -100 | -99 | -87 | N/A |
12/31/2018 | 13 | -71 | -89 | -74 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 5CV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 5CV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 5CV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 5CV's revenue (31.6% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: 5CV's revenue (31.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 5CV is forecast to be unprofitable in 3 years.